Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children

Torsak Bunupuradah, Thanyawee Puthanakit, Pope Kosalaraksa, Stephen Kerr, Pitch Boonrak, Wasana Prasitsuebsai, Pagakrong Lumbiganon, Tawan Mengthaisong, Chayapa Phasomsap, Chitsanu Pancharoen, Kiat Ruxrungtham, Jintanat Ananworanich, Torsak Bunupuradah, Thanyawee Puthanakit, Pope Kosalaraksa, Stephen Kerr, Pitch Boonrak, Wasana Prasitsuebsai, Pagakrong Lumbiganon, Tawan Mengthaisong, Chayapa Phasomsap, Chitsanu Pancharoen, Kiat Ruxrungtham, Jintanat Ananworanich

Abstract

Background: There are limited data of immunologic and virologic failure in Asian HIV-infected children using non-nucleoside reverse transcriptase inhibitor (NNRTI)-based highly active antiretroviral therapy (HAART). We examined the incidence rate of immunologic failure (IF) and virologic failure (VF) and the accuracy of using IF to predict VF in Thai HIV-infected children using first-line NNRTI-based HAART.

Methods: Antiretroviral (ART)-naïve HIV-infected children from 2 prospective cohorts treated with NNRTI-based HAART during 2001-2008 were included. CD4 counts were performed every 12 weeks and plasma HIV-RNA measured every 24 weeks. Immune recovery was defined as CD4%≥25%. IF was defined as persistent decline of ≥5% in CD4% in children with CD4%<15% at baseline or decrease in CD4 count ≥30% from baseline. VF was defined as HIV-RNA>1,000 copies/ml after at least 24 weeks of HAART. Clinical and laboratory parameter changes were assessed using a paired t-test, and a time to event approach was used to assess predictors of VF. Sensitivity and specificity of IF were calculated against VF.

Results: 107 ART-naive HIV-infected children were included, 52% female, % CDC clinical classification N:A:B:C 4:44:30:22%. Baseline data were median (IQR) age 6.2 (4.2-8.9) years, CD4% 7 (3-15), HIV-RNA 5.0 (4.9-5.5) log10copies/ml. Nevirapine (NVP) and efavirenz (EFV)-based HAART were started in 70% and 30%, respectively.At 96 weeks, none had progressed to a CDC clinical classification of AIDS and one had died from pneumonia. Overall, significant improvement of weight for age z-score (p = 0.014), height for age z-score, hemoglobin, and CD4 were seen (all p < 0.001). The median (IQR) CD4% at 96 weeks was 25 (18-30)%. Eighty-nine percent of children had immune recovery (CD4%≥25%) and 75% of children had HIV-RNA <1.7log10copies/ml.Thirty five (32.7%) children experienced VF within 96 weeks. Of these, 24 (68.6%) and 31 (88.6%) children had VF in the first 24 and 48 weeks respectively.Only 1 (0.9%) child experienced IF within 96 weeks and the sensitivity (95%CI) of IF to VF was 4 (0.1-20.4)% and specificity was 100 (93.9-100)%.

Conclusion: Immunologic failure, as defined here, had low sensitivity compared to VF and should not be recommended to detect treatment failure. Plasma HIV-RNA should be performed twice, at weeks 24 and 48, to detect early treatment failure.

Trial registration: Clinicaltrials.gov identification number NCT00476606.

Figures

Figure 1
Figure 1
Kaplan-Meier proportion of virologic failure.

References

    1. 2008 Report on the Global AIDS epidemic. UNAIDS/WHO. 2008.
    1. Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T. et al.Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41(1):100–7. doi: 10.1086/430714.
    1. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S, Wannarit P. et al.Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. The Pediatric infectious disease journal. 2007;26(10):953–6. doi: 10.1097/INF.0b013e318125720a.
    1. Rajasekaran S, Jeyaseelan L, Ravichandran N, Gomathi C, Thara F, Chandrasekar C. Efficacy of antiretroviral therapy program in children in India: prognostic factors and survival analysis. Journal of tropical pediatrics. 2009;55(4):225–32. doi: 10.1093/tropej/fmm073.
    1. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. The Pediatric infectious disease journal. 2009;28(9):826–30. doi: 10.1097/INF.0b013e3181a458f9.
    1. Janssens B, Raleigh B, Soeung S, Akao K, Te V, Gupta J. et al.Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120(5):e1134–40. doi: 10.1542/peds.2006-3503.
    1. Renaud-Thery F, Nguimfack BD, Vitoria M, Lee E, Graaff P, Samb B. et al.Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS (London, England) 2007;21(Suppl 4):S89–95. doi: 10.1097/01.aids.0000279711.54922.f0.
    1. Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS (London, England) 2006;20(11):1497–502. doi: 10.1097/01.aids.0000237365.18747.13.
    1. Sirivichayakul S, Chantratita W, Sutthent R, Ruxrungtham K, Phanuphak P, Oelrichs RB. Survey of reverse transcriptase from the heterosexual epidemic of human immunodeficiency virus type 1 CRF01_AE in Thailand from 1990 to 2000. AIDS research and human retroviruses. 2001;17(11):1077–81. doi: 10.1089/088922201300343762.
    1. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access: recommendations for a public health approach 2010 revision
    1. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS (London, England) 2008;22(15):1971–7. doi: 10.1097/QAD.0b013e32830e4cd8.
    1. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F. et al.Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009;49(3):454–62. doi: 10.1086/600396.
    1. Emmett SD, Cunningham CK, Mmbaga BT, Kinabo GD, Schimana W, Swai ME. et al.Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. Journal of acquired immune deficiency syndromes (1999) 2010;54(4):368–75.
    1. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Geneva: WHO; 2006.
    1. Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P. et al.Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008;91(12):1925–35.
    1. Division of AIDS table for grading the severity of adult and pediatric adverse events. 2004.
    1. Puthanakit T, Kerr SJ, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. The Pediatric infectious disease journal. 2009.
    1. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2005.
    1. Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoepelman AI, Geelen SP. Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment. Pediatr Infect Dis J. pp. 52–6.
    1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. et al.Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. doi: 10.1161/CIRCULATIONAHA.105.169404.
    1. Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA, Richardson BA. et al.Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. Journal of acquired immune deficiency syndromes (1999) 2007;45(3):311–7.
    1. Wamalwa DC, Obimbo EM, Farquhar C, Richardson BA, Mbori-Ngacha DA, Inwani I. et al.Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort. BMC pediatrics. 2010;10:33. doi: 10.1186/1471-2431-10-33.
    1. Vaz P, Chaix ML, Jani I, Macassa E, Bila D, Vubil A. et al.Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure. The Pediatric infectious disease journal. 2009;28(12):e283–7. doi: 10.1097/INF.0b013e3181ba6c92.
    1. Ciaranello AL, Chang Y, Margulis AV, Bernstein A, Bassett IV, Losina E. et al.Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009;49(12):1915–27. doi: 10.1086/648079.
    1. Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, Kaldor JM. et al.Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV medicine. 2007;8(7):465–71. doi: 10.1111/j.1468-1293.2007.00498.x.
    1. Gray D, Nuttall J, Lombard C, Davies MA, Workman L, Apolles P. et al.Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis. Journal of tropical pediatrics. 2010;56(3):159–65. doi: 10.1093/tropej/fmp079.
    1. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye J. et al.Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS (London, England) 2009;23(6):661–72.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner